Netrin 1和α-甲基酰基辅酶A消旋酶在前列腺癌诊断中的应用

Netrin 1 and Alpha-Methyl Acylcoenzim-A Racemase in diagnosis of prostate cancer.

作者信息

Koseoglu Ersin, Tuncel Altug, Balci Melih, Kaya Oguzhan, Aslan Yilmaz, Guzel Ozer, Yilmaz Fatma Meric, Atan Ali

机构信息

Ankara Numune Research and Training Hospital, Department of Urology. Ankara, Turkey.

Ankara Numune Research and Training Hospital, Department of Biochemistry. Ankara,Turkey.

出版信息

Colomb Med (Cali). 2018 Jun 30;49(2):164-168. doi: 10.25100/cm.v49i2.3011.

DOI:10.25100/cm.v49i2.3011

PMID:30104809

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6084917/

Abstract

OBJECTIVES

To investigate serum and urine levels of Alpha-methylacyl-CoA-racemase (AMACR) and Netrin 1 in patients with and without prostate cancer and to determine whether these markers could be used as alternatives in diagnosis of prostate cancer instead of serum prostate specific antigen (PSA) levels.

METHODS

One hundred and seventy five patients between 45-75 years to whom transrectal ultrasound guided biopsies were performed for abnormal serum PSA levels or digital rectal examinations were included. The levels of AMACR and Netrin 1 levels of blood and urine samples of 5 mL those were taken prior to biopsies were measured. .

RESULTS

The mean age of the patients was 62.7 ±6.4 years. Prostate cancer was detected in 40 patients (22.8%) while 135 of them (77.2%) were diagnosed as benign prostate hyperplasia (BPH). In BPH group, serum and urine levels of AMACR and Netrin 1 were 13.4 ±16.9 ng/mL; 7.1 ±3.4 ng/mL; 164.1±46 pg/mL and 19.5 ±5.0 pg/mL respectively. The levels of serum and urine levels of AMACR and Netrin 1 were 10.2 ±9.8 ng/mL; 6.8 ±2.5 ng/mL; 159.1 ±44.1 pg/mL and 20.1 ±5.3 pg/mL respectively in prostate cancer group. There was no statistically significant difference or correlation between these two groups serum and urine AMACR and Netrin 1 results.

CONCLUSIONS

Serum and urine levels of AMACR and Netrin 1 were not found to be alternatives for serum PSA levels in the diagnosis of prostate cancer in this study.

摘要

目的

研究前列腺癌患者与非前列腺癌患者血清及尿液中α-甲基酰基辅酶A消旋酶（AMACR）和Netrin 1的水平，并确定这些标志物是否可替代血清前列腺特异性抗原（PSA）水平用于前列腺癌的诊断。

方法

纳入175例年龄在45 - 75岁之间的患者，这些患者因血清PSA水平异常或直肠指检异常而接受经直肠超声引导下活检。测量活检前采集的5 mL血液和尿液样本中AMACR和Netrin 1的水平。

结果

患者的平均年龄为62.7±6.4岁。40例患者（22.8%）检测出前列腺癌，其中135例（77.2%）被诊断为良性前列腺增生（BPH）。在BPH组中，AMACR和Netrin 1的血清及尿液水平分别为13.4±16.9 ng/mL；7.1±3.4 ng/mL；164.1±46 pg/mL和19.5±5.0 pg/mL。前列腺癌组中AMACR和Netrin 1的血清及尿液水平分别为10.2±9.8 ng/mL；6.8±2.5 ng/mL；159.1±44.1 pg/mL和20.1±5.3 pg/mL。两组血清及尿液中AMACR和Netrin 1的结果之间无统计学显著差异或相关性。